Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Stopped early · Not applicable

Conditions studied: Chronic Kidney Disease Stages 3-5

In brief

Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.

Key facts

Study ID
NCT01263028
Run by
Kaiser Permanente
People needed
6
Starts
2010-08-01
Expected to finish
2011-09-01
Last updated by the study team
2015-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.